CD8A and neoplasm: Vaccination with neoantigen-pulsed DC in mice demonstrated a stronger antigen-specific lymphocyte response, increased number of TILs including CD8+ and CD8+IFN-γ+ T cells, and inhibited tumor growth, compared to the neoantigen-adjuvant vaccination.